About VERAXA
VERAXA is a company based in Heidelberg (Germany) founded in 2017 by Edward A. Lemke, Christoph A. Merten, and Christine Köhler. VERAXA has raised $3.41 million across 1 funding round. VERAXA has completed 1 acquisition, including SYNIMMUNE. VERAXA offers products and services including BiTAC Technology, ADC Technology, and Functional Antibody Screening. VERAXA operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Heidelberg, Germany
- Founders Edward A. Lemke, Christoph A. Merten, Christine Köhler
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Veraxa Biotech Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.41 M (USD)
in 1 rounds
-
Latest Funding Round
$3.41 M (USD), Series B
Jun 27, 2019
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VERAXA
VERAXA offers a comprehensive portfolio of products and services, including BiTAC Technology, ADC Technology, and Functional Antibody Screening.
Platform for bispecific T-cell engagers in oncology treatments.
Technology for antibody-drug conjugates targeting cancer with reduced side effects.
Method for screening antibodies to enhance therapeutic development.
People of VERAXA
Unlock access to complete
Unlock access to complete
Funding Insights of VERAXA
VERAXA has successfully raised a total of $3.41M through 1 strategic funding round. The most recent funding activity was a Series B round of $3.41 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by VERAXA
VERAXA has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SYNIMMUNE.
Investment portfolio details for VERAXA
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
German, early-stage biotech developing mono- and bi-specific antibodies for cancer treatment
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for VERAXA
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - VERAXA
Detailed financials for VERAXA
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Veraxa Comparisons
Peer comparison for VERAXA
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VERAXA
VERAXA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of VERAXA
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Veraxa
Complete news archive for VERAXA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VERAXA
VERAXA was founded in 2017 and raised its 1st funding round 2 years after it was founded.
VERAXA is headquartered in Heidelberg, Germany. It is registered at Heidelberg, Baden-wurttemberg, Germany.
VERAXA is a funded company, having raised a total of $3.41M across 1 funding round to date.
VERAXA was founded in 2017 in Heidelberg, Germany, within the biotechnology sector. Antibody therapeutics for oncological conditions are developed through ADC engineering and functional antibody screening. Droplet-based microfluidic screening technology is utilized, along with innovative antibody and protein conjugation methods, to generate antibodies against complex target molecules. Operations focus on advancing treatments for cancer.
VERAXA's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
VERAXA offers BiTAC Technology, ADC Technology, and Functional Antibody Screening.
VERAXA has made 1 acquisition, including SYNIMMUNE.